Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.
Also called NCT05632445
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose diagnostic
- Phase
- Phase 4
- Enrolled
- 160 participants
- Sponsor
- DR. XAVIER FREIXA
- Registry
-
NCT05632445
-
- Other papers using this trial's data
- Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT05632445. Randomized; single masking; primary purpose diagnostic. Start 2019-05-01 (actual); primary completion 2019-06-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
- Acronym
- ADALA
- Condition
- Left Atrial Appendage Occlusion
- Intervention (Drug)
- Apixaban vs. DAPT
- Lead sponsor
- DR. XAVIER FREIXA
Record details
- Record id
cardio:ct-nct05632445- Content hash
c2256a2b85b5744ca214c856b6980bf3e2f4c7206e9efac997f33bfacf397bd5